Selective estrogen receptor (ER) modulators and downregulators (SERMs and SERDs, also refereed to as anti-hormones) have saved the lives of millions of women with ER-positive breast cancer. Unfortunately, approximately one-third of these women display intrinsic resistance to these targeted therapies, while a similar fraction of women treated with anti-hormones will develop resistance over time, resulting in recurrences of often more aggressive cancers. SERMs and SERDs inhibit the classical nuclear estrogen receptor ER?, leading to the inhibition of cell proliferation and survival. In contrast, our results have shown that these same drugs activate the 7-transmembrane spanning G protein-coupled estrogen receptor GPER, resulting in the stimulation of the pro-survival PI3K/Akt axis. Furthermore, our recent studies have suggested that this may occur through phosphorylation and inactivation of the FOXO3 pro-apoptotic transcription factor. We have identified a collection of novel compounds that display strong selectivity for either ER? or GPER. By combining these pharmacological approaches with genetic approaches, we hypothesize that acquired resistance to anti-hormones involves their activation of GPER, resulting in the inactivation of FOXO3. We propose to test this hypothesis with the following specific aims:
Aim 1 will test whether GPER mediates acquired breast cancer resistance to SERMs and SERDs.
Aim 2 will test whether the inactivation of FOXO3 represents a critical step in enhancing tumor cell survival in the face of ER? inhibition.
Aim 3 will employ a murine model of spontaneous breast cancer to test whether blocking GPER activity in combination with tamoxifen treatment, or alternatively selectively inhibiting ER? with novel drugs, prevents acquired resistance. Significance: Completion of these aims will significantly advance our knowledge of the role of the novel estrogen receptor GPER in acquired anti-hormone resistance in breast cancer. Identifying GPER as a novel mediator in acquired anti-hormone resistance in breast cancer in combination with the use novel highly selective ligands to be evaluated in this proposal could lead to significant improvements in outcome for the150,000 women diagnosed with ER-positive breast cancer each year.
Tamoxifen and similar drugs have been highly successful in treating women with breast cancer. However, despite initial effectiveness, resistance to these drugs occurs in about one-third of women. This study will determine the role of a novel estrogen receptor named GPER in tamoxifen resistance and test the ability of a novel and unique drug lead with improved target selectivity to prevent or limit breast cancer recurrence and resistance.
| Castleman, Moriah J; Pokhrel, Srijana; Triplett, Kathleen D et al. (2018) Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by ?-Hemolysin. J Immunol 200:657-668 |
| Barton, Matthias; Filardo, Edward J; Lolait, Stephen J et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol 176:4-15 |
| Prossnitz, Eric R (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol 176:73-81 |
| Arias-Pulido, H; Cimino-Mathews, A; Chaher, N et al. (2018) The combined presence of CD20?+?B cells and PD-L1?+?tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat 171:273-282 |
| Peretti, Amanda S; Dominguez, Dayna; Grimes, Martha M et al. (2018) The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice. Am J Pathol 188:515-524 |
| Prossnitz, Eric R (2018) New developments in the rapid actions of steroids and their receptors. J Steroid Biochem Mol Biol 176:1-3 |
| Sharma, Geetanjali; Mauvais-Jarvis, Franck; Prossnitz, Eric R (2018) Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. J Steroid Biochem Mol Biol 176:31-37 |
| Marcus, Jenna Z; Klobocista, Merieme; Karabakhtsian, Rouzan G et al. (2018) Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. Int J Gynecol Cancer 28:500-504 |
| Hill, Deirdre A; Friend, Sarah; Lomo, Lesley et al. (2018) Breast cancer survival, survival disparities, and guideline-based treatment. Breast Cancer Res Treat 170:405-414 |
| Fredette, Natalie C; Meyer, Matthias R; Prossnitz, Eric R (2018) Role of GPER in estrogen-dependent nitric oxide formation and vasodilation. J Steroid Biochem Mol Biol 176:65-72 |
Showing the most recent 10 out of 37 publications
